ClinicalTrials.gov record
Terminated Phase 1 Interventional

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

ClinicalTrials.gov ID: NCT04553692

Public ClinicalTrials.gov record NCT04553692. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 5:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Multicenter, Phase 1a/1b Study of Aplitibart (IGM-8444) As a Single Agent and in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Study identification

NCT ID
NCT04553692
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
IGM Biosciences, Inc.
Industry
Enrollment
272 participants

Conditions and interventions

Interventions

  • Aplitabart (IGM-8444) Drug
  • Azacitidine Drug
  • Bevacizumab (and approved biosimilars) Drug
  • Birinapant Drug
  • Docetaxel Drug
  • FOLFIRI Drug
  • Gemcitabine Drug
  • Venetoclax Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 22, 2020
Primary completion
Jan 19, 2025
Completion
Jan 19, 2025
Last update posted
Mar 27, 2025

2020 – 2025

United States locations

U.S. sites
37
U.S. states
19
U.S. cities
32
Facility City State ZIP Site status
Mayo Clinic Phoenix Arizona 85054
City of Hope Comprehensive Cancer Center Duarte California 91010
Cancer and Blood Specialty Clinic (CBSC) Los Alamitos California 90720
USC Norris Los Angeles California 90033
UCLA Los Angeles California 90404
UC Irvine Manchester Pavilion Orange California 92868
UCSF San Francisco California 94143
Rocky Mountain Cancer Centers Denver Colorado 80218
SCRI at Healthone Denver Colorado 80218
Yale Cancer Center New Haven Connecticut 06510
Mayo Clinic Jacksonville Florida 32224
FL Cancer Specialists - Lake Mary Lake Mary Florida 32746
Memorial Cancer Institute Pembroke Pines Florida 33028
Florida Cancer Specialists Sarasota Florida 34232
Fort Wayne Medical Oncology and Hematology Fort Wayne Indiana 46804
Norton Cancer Institute Louisville Kentucky 40241
Ochsner Cancer Jefferson Louisiana 70121
Maryland Oncology Hematology, PA - Columbia Columbia Maryland 21044
START Midwest Grand Rapids Michigan 49546
Minnesota Oncology - Minneapolis Clinic Minneapolis Minnesota 55404
Mayo Clinic Minneapolis Minnesota 55905
Washington University School of Medicine St Louis Missouri 63110
Gabrail Cancer Research Canton Ohio 44718
Stephenson Cancer Center Oklahoma City Oklahoma 73104
Providence Portland Medical Center Portland Oregon 97213
SCRI - Tennessee Nashville Tennessee 37203
Texas Oncology - Austin Austin Texas 78705
Mary Crowley Cancer Research Dallas Texas 75230
US Oncology - Dallas Dallas Texas 75246
US Oncology- Texas Oncology - Fort Worth Fort Worth Texas 76104
The University of Texas, MD Anderson Houston Texas 77030
Texas Oncology - San Antonio Northeast San Antonio Texas 78217
Texas Oncology - Tyler Tyler Texas 75702
Inova Schar Cancer Institute Fairfax Virginia 22031
Virginia Cancer Specialists Fairfax Virginia 22031
US Oncology- Virginia Oncology - Norfolk Norfolk Virginia 23502
Seattle Cancer Alliance - Fred Hutch Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04553692, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 27, 2025 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04553692 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →